Thymosin Beta-4 is a ubiquitous protein present in virtually every cell of the body that regulates actin, the structural protein forming the cellular cytoskeleton. TB-500 has been a standard protocol in equine sports medicine for over a decade and is now increasingly studied in canine and feline applications for mobility, injury recovery, and cardiac protection.
TB-500 works primarily through actin regulation. Actin polymerization and depolymerization is essential for cell migration, wound healing, and tissue repair. By binding to G-actin and sequestering it, TB-500 promotes the migration of endothelial cells, keratinocytes, and repair cells to sites of injury, accelerating the natural healing cascade.
TB-500 upregulates anti-inflammatory pathways and reduces systemic markers of inflammation. It promotes angiogenesis through VEGF-independent mechanisms, creating new blood supply to injured tissue without the hormonal side effects of growth factor therapies.
Additionally, TB-500 has documented cardioprotective effects. It has been shown to promote cardiomyocyte survival after ischemic events and support regeneration of cardiac tissue, making it uniquely valuable for older animals with cardiac risk factors.
| Weight | Species | Dose | Frequency | Administration |
|---|---|---|---|---|
| Under 20 lbs | Dog / Cat | 0.5 mg | Twice weekly | Subcutaneous |
| 20–50 lbs | Dog | 1 mg | Twice weekly | Subcutaneous |
| 50–100 lbs | Dog | 1.5–2 mg | Twice weekly | Subcutaneous |
| Over 100 lbs | Dog | 2–2.5 mg | Twice weekly | Subcutaneous |
| Under 10 lbs | Cat | 0.25 mg | Twice weekly | Subcutaneous |
Every batch shipped by Peptail is independently tested by a third-party analytical laboratory. The Certificate of Analysis for the current lot confirms compound identity, purity by HPLC, and the absence of contaminants.
Opens PDF in a new tab. Updated with each new lot.